EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists

Nour Ghostine, Maya Halabi‐Tawil

JEADV Clinical Practice · 2026-06 · 5 (2) · 606-609

DOI: 10.1002/jvc2.70266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JEADV Clinical Practice, online erschienen am 29.01.2026. Verfasst von Nour Ghostine und 1 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review.

Objectives

This systematic review aims to assess dermatological manifestations associated with GLP‐1 RA therapy, highlighting both adverse effects and potential therapeutic benefits.

Methods

Following the PRISMA guidelines, articles that evaluated dermatological outcomes in patients receiving GLP‑1 RAs were systematically searched using PubMed and ScienceDirect databases. Only randomized controlled trials (RCTs) and observational studies involving human subjects were included.

Results

Hair loss was the most significant side effect, unlike the usually reported injection‐site reactions or lipodystrophy. Interestingly, several studies found that liraglutide and semaglutide therapy improved psoriasis lesions.

Conclusions

The most frequent side effect associated with GLP1‐RA use in this review appeared to be hair loss. Importantly, some GLP1‐RAs have been shown to improve psoriatic lesions.

Zitieren

APA

Ghostine, N., & Halabi‐Tawil, M. (2026). Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists. JEADV Clinical Practice, 5(2), 606-609. https://doi.org/10.1002/jvc2.70266

Vancouver

Ghostine N, Halabi‐Tawil M. Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists. JEADV Clinical Practice. 2026;5(2):606-609. doi:10.1002/jvc2.70266

BibTeX
@article{Ghostine2026,
  author = {Ghostine, Nour and Halabi‐Tawil, Maya},
  title = {Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists},
  journal = {JEADV Clinical Practice},
  year = {2026},
  volume = {5},
  number = {2},
  pages = {606--609},
  doi = {10.1002/jvc2.70266}
}
Kostenlos starten →